|
GBGB2108302.7A
GB202108302D0
(en)
|
2021-06-10 |
2021-06-10 |
New treatment
|
|
US18/568,160
US20240285642A1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
DK22732626.1T
DK4337191T3
(en)
|
2021-06-10 |
2022-06-09 |
EGFR inhibitor for the treatment of head and neck cancer
|
|
HRP20250177TT
HRP20250177T1
(en)
|
2021-06-10 |
2022-06-09 |
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
|
|
MA69391A
MA69391B1
(en)
|
2021-06-10 |
2022-06-09 |
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
|
|
SI202230087T
SI4337191T1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
CN202280042824.8A
CN117545476B
(en)
|
2021-06-10 |
2022-06-09 |
EGFR inhibitors for the treatment of head and neck cancer
|
|
MX2023014729A
MX2023014729A
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer.
|
|
BR112023025903A
BR112023025903A2
(en)
|
2021-06-10 |
2022-06-09 |
COMPOUND FOR USE IN THE TREATMENT OF SQUAMOUS CELL CARCINOMA, COMPOUND FOR USE IN THE TREATMENT OF HEAD AND NECK CANCER, METHODS FOR TREATING SQUAMOUS CELL CARCINOMA AND FOR TREATING HEAD AND NECK CANCER AND USES OF A COMPOUND
|
|
SM20250035T
SMT202500035T1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
RS20250132A
RS66487B1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
ES22732626T
ES3007384T3
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
EP22732626.1A
EP4337191B1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
HUE22732626A
HUE070017T2
(en)
|
2021-06-10 |
2022-06-09 |
EGFR inhibitor for the treatment of head and neck cancer
|
|
PCT/GB2022/051450
WO2022258977A1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
JP2023575997A
JP7579465B2
(en)
|
2021-06-10 |
2022-06-09 |
EGFR INHIBITORS FOR THE TREATMENT OF HEAD AND NECK CANCER - Patent application
|
|
KR1020247000892A
KR102713072B1
(en)
|
2021-06-10 |
2022-06-09 |
EGFR inhibitors for head and neck cancer treatment
|
|
PL22732626.1T
PL4337191T3
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
CA3221808A
CA3221808A1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
FIEP22732626.1T
FI4337191T3
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
AU2022291015A
AU2022291015A1
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
PT227326261T
PT4337191T
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
IL309181A
IL309181A
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
LTEPPCT/GB2022/051450T
LT4337191T
(en)
|
2021-06-10 |
2022-06-09 |
EGFR INHIBITOR FOR THE TREATMENT OF HEAD AND NECK CANCER
|
|
GEAP202416421A
GEAP202416421A
(en)
|
2021-06-10 |
2022-06-09 |
Egfr inhibitor for the treatment of head and neck cancer
|
|
CL2023003673A
CL2023003673A1
(en)
|
2021-06-10 |
2023-12-07 |
EGFR inhibitor for the treatment of head and neck cancer
|
|
ZA2023/11291A
ZA202311291B
(en)
|
2021-06-10 |
2023-12-07 |
Egfr inhibitor for the treatment of head and neck cancer
|